Protein Discovery Holds Promise in Addressing Prostate Cancer Medicine Resistance

Published by admin on

Scientists have identified CHRM1, a receptor protein linked to the resistance of prostate cancer cells to docetaxel, an advanced cancer chemotherapy drug. Published in Cell Reports Medicine, this discovery unveils innovative treatment strategies that could potentially extend the lives of individuals with various cancers, including prostate cancer. Through the use of dicyclomine to inhibit CHRM1 in resistant prostate cancer cells, researchers successfully reinstated docetaxel’s effectiveness in eradicating cancer cells and impeding tumor growth. The positive outcomes of combining dicyclomine and docetaxel propose a more potent treatment approach, with potential applications in other cancers treated with docetaxel, such as breast and lung cancer.

Checkout this effective supplement to keep your prostate healthy!

Employing dicyclomine, a drug typically used for irritable bowel syndrome and known for selectively inhibiting CHRM1 activity, researchers successfully impeded CHRM1 in both resistant prostate cancer cell lines and animal models derived from patient-resistant tissue. This intervention proved effective in restoring docetaxel’s capability to eliminate cancer cells and halt tumor growth.

The rapid development of docetaxel resistance within six months of treatment poses a substantial hurdle for patients with castration-resistant prostate cancer who turn to chemotherapy following hormone therapy failure. The study strongly advocates for clinical trials to assess the combined impact of docetaxel and dicyclomine in overcoming treatment resistance in prostate cancer patients.

Moreover, the research team observed that blocking CHRM1 in cancer cells heightened the efficiency of docetaxel, suggesting potential advantages for prostate cancer patients through a combined treatment approach, even before resistance to docetaxel emerges. Study author Boyang (Jason) Wu from Washington State University underscores that combining docetaxel with dicyclomine may enable the use of a lower effective dose, potentially reducing undesirable side effects and enhancing the manageability of treatment for patients.

The research team is excited to carry out more research and evaluate the potential of combination therapy for other cancers treated with docetaxel, such as lung and breast cancer. They also intend to investigate the possibility of applying the developed combination strategy to other chemotherapy drugs that share comparable features. The current study aims to increase the therapeutic approach’s efficacy against different cancer types and expand its possible applications.

Also read: Natural Foods That Cure Erectile Dysfunction